Share on StockTwits

Shares of Bruker (NASDAQ:BRKR) have earned a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the stock, Analyst Ratings.Net reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $25.60.

Shares of Bruker (NASDAQ:BRKR) opened at 20.32 on Friday. Bruker has a 52-week low of $17.75 and a 52-week high of $24.93. The stock has a 50-day moving average of $22.74 and a 200-day moving average of $22.20. The company has a market cap of $3.410 billion and a P/E ratio of 43.64.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.02. The company had revenue of $457.40 million for the quarter, compared to the consensus estimate of $457.90 million. During the same quarter in the previous year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. On average, analysts predict that Bruker will post $0.80 earnings per share for the current fiscal year.

BRKR has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Bruker from an “outperform” rating to a “neutral” rating in a research note on Monday, August 11th. They now have a $25.40 price target on the stock. Separately, analysts at Citigroup Inc. initiated coverage on shares of Bruker in a research note on Thursday, July 17th. They set a “buy” rating on the stock. Finally, analysts at ISI Group downgraded shares of Bruker from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 8th. They now have a $25.50 price target on the stock.

Bruker Corporation (NASDAQ:BRKR) is a global manufacturer of scientific instruments that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.